Calcium/Calmodulin Signalling: Architecture and Key Effectors
Calcium (Ca2+; the universal second messenger; intracellular [Ca2+] resting ~100 nM; cytoplasmic Ca2+ transients during signalling: ~0.1–10 µM; sources: ER (primary intracellular store; [Ca2+]ER ~400–800 µM); mitochondria (Ca2+ uptake via MCU; Ca2+ stimulates PDH/ICDH/OGDH → TCA/ATP); extracellular (~1.2 mM plasma Ca2+; voltage-gated (VGCC: L/N/P/Q/R/T-type), receptor-operated (ROCC; NMDAR; P2X), store-operated (SOCE; STIM1/Orai1)); Ca2+ release channels: IP3R (inositol 1,4,5-trisphosphate receptor; ER membrane; IP3 gating; three isoforms IP3R1/2/3; Ca2+ permeability ~10^7 Ca2+/s; modulated by: Ca2+ itself (biphasic: low Ca2+ activates; high Ca2+ inhibits), ATP, redox (Cys2547/Cys2613 thiol oxidation → IP3R activation; relevant to oxidative stress amplification); RyR (ryanodine receptor; SR/ER; RyR1 skeletal/RyR2 cardiac; CICR (Ca2+-induced Ca2+ release); redox-sensitive Cys residues; CaM binding site; caffeine-sensitive)); SERCA (sarco/ER Ca2+-ATPase; SERCA2b (ubiquitous ER); ATP-dependent Ca2+ re-uptake; Cys674 (reversible sulphenylation → SERCA enhancement; irreversible oxidation → SERCA inhibition); PLN (phospholamban; SERCA2a inhibitor in cardiac; pSer16/pThr17 relieves inhibition)); calmodulin (CaM; 16.7 kDa; EF-hand Ca2+ binding protein; 4 Ca2+ binding sites (EF1–4; KD ~0.1–10 µM); Ca2+/CaM activates: CaMKII (α/β/γ/δ isoforms; Thr286 autophosphorylation → constitutive activity after Ca2+ signal; major cardiac/neuronal kinase), calcineurin (CaN; PP2B; RCAN1 inhibitor; dephosphorylates NFAT: NFAT1–4; nuclear translocation → IL-2/TNF-α/NFAT-dependent gene expression; CsA/tacrolimus target), eNOS (endothelial NOS; Ca2+/CaM binding domain Arg1059-Val1080; CaM binding → eNOS activation → NO), nNOS (neuronal NOS; Ca2+/CaM-dependent; synaptic plasticity), MLCK (myosin light chain kinase; smooth muscle contraction; CaM-dependent; MLC-P → actin-myosin interaction), CaM-kinase I/IV (gene expression; CREB Ser133))).
Spirulina Mechanisms in Calcium/Calmodulin Signalling
IP3R/SERCA Ca2+ Homeostasis
IP3R (the primary ER Ca2+ release channel; IP3 from PLC-β/γ PI(4,5)P2 hydrolysis; IP3R1 most sensitive; Cys2547 thiol: oxidation → IP3R open probability ↑ → Ca2+ leak from ER → cytoplasmic Ca2+ elevation → CaMKII/calcineurin/PKC amplification) is indirectly modulated by spirulina through: (1) Nrf2-PRX4 (ER-lumen peroxiredoxin; thiol peroxidase; reduces H2O2/ROOH in ER lumen; prevents IP3R Cys2547 oxidation → IP3R Ca2+ release −15–25% in ER-stressed cells); (2) PKC-α/βII suppression (−25–40% PCB IC50 ~5–20 µM; PKC-α phosphorylates PLC-δ → IP3 production feedback; less PKC → less IP3 → less IP3R activation); (3) SERCA2b Cys674 protection (Nrf2-TRX1/GSH → Cys674 maintained in reduced/sulphenylated (activating) form vs. irreversibly oxidised (inhibiting) form; SERCA2b Cys674 sulphenylation enhances pump velocity ~20–30% → faster Ca2+ re-uptake; GSH-deficient cells: SERCA2b Cys674 sulphonylation → pump inhibition → ER Ca2+ depletion → STIM1-Orai1 SOCE activation). STIM1/Orai1 (store-operated Ca2+ entry; STIM1 ER-membrane sensor (EF-hand; Ca2+ dissociation → STIM1 oligomerisation → puncta at ER-PM junctions → Orai1 channel gating → CRAC current); SOCE activates: CaMKII, calcineurin-NFAT, NFAT1–4 → cytokine gene expression): spirulina SERCA2b support → ER Ca2+ restored faster → STIM1 re-loading → SOCE duration −10–20%; net: attenuated pathological Ca2+ overload while preserving physiological Ca2+ transients.
CaMKII Autophosphorylation Attenuation
CaMKII (Ca2+/calmodulin-dependent protein kinase II; major cardiac and neuronal kinase; dodecameric holoenzyme (12 subunits; α/β/γ/δ); activation: Ca2+/CaM → Thr286 autophosphorylation (in trans; → constitutive activity independent of Ca2+; ‘molecular memory’); deactivation: PP2A dephosphorylation; CaMKII substrates: RyR2 Ser2808/Ser2814 (cardiac arrhythmia), PLN Thr17 (SERCA2a activation), HDAC4/5 Ser246/632 (nuclear export → MEF2 activation → hypertrophy), synapsin I Ser603 (neurotransmitter release), AMPAR Ser831 (LTP); oxidative activation: CaMKII Met281/282 oxidation (→ constitutive activity; equivalent to Thr286 phospho; relevant in ischaemia/reperfusion, β-AR stimulation); CaMKII hyperactivation: cardiac hypertrophy/arrhythmia, neuronal excitotoxicity, T cell NFAT activation): spirulina reduces CaMKII hyperactivation through: (1) IP3R/Ca2+ transient amplitude reduction (−15–25%) → less Ca2+/CaM availability for CaMKII Thr286 autophosphorylation; (2) Nrf2-TRX (reduces Met281/282 back to Met → less oxidative CaMKII constitutive activity; TXNRD1/TRX1 +25–40%); (3) AMPK (AMPK Thr172 → indirect CaMKII downregulation in cardiomyocyte models; AMPK-PP2A activation → CaMKII Thr286 dephosphorylation). Net: CaMKII Thr286 phospho −10–20% in inflammatory/oxidative models; preserved physiological CaMKII signalling for LTP/cardiac contractility.
Calcineurin-NFAT Pathway Modulation
Calcineurin (CaN; PP2B; serine/threonine phosphatase; heterodimer (CnA catalytic + CnB regulatory; CnB Ca2+-binding EF-hands); Ca2+/CaM-activated; primary substrates: NFAT1–4 (nuclear factor of activated T cells; Ser/Pro-rich domain; 13 Ser residues; phospho-NFAT → cytoplasmic (bound by 14-3-3); dephospho → nuclear; transcription: IL-2/IL-4/IL-5/IL-13/TNF-α T cell activation; VEGF cardiac hypertrophy; osteoclast NFATc1 → RANKL-driven bone resorption); CaN inhibitors: cyclosporin A (CsA; binds cyclophilin A → CsA-CypA complex → CaN inhibition); FK506/tacrolimus (binds FKBP12 → FKBP12-FK506 → CaN inhibition); RCAN1/DYRK1A (endogenous CaN inhibitors; RCAN1 inducible by Ca2+/NFAT (positive feedback limit))): spirulina attenuates calcineurin-NFAT pathway through: (1) Ca2+ transient reduction (−15–25%) → less CaN activation by Ca2+/CaM; (2) NF-κB suppression (−30–45%; PCB NF-κB IKKβ) which converges on same pro-inflammatory target genes as NFAT (IL-2/TNF-α/IL-6; NF-κB + NFAT co-activate many cytokine promoters; NF-κB inhibition alone reduces NFAT transcriptional output even without direct NFAT inhibition); (3) RCAN1 upregulation (NFAT → RCAN1 induction is a negative feedback; if early NFAT activity is preserved for physiological signalling but amplified pathological Ca2+ is suppressed, RCAN1 natural feedback is enhanced); (4) eNOS-NO (NO → sGC → cGMP → PKG → NFAT Ser172 phosphorylation → NFAT export; NO pathway preserved/enhanced by spirulina → NFAT nuclear retention suppressed). Net: NFAT-driven IL-2/IL-5 −15–25% in activated T cells; allergy/asthma NFAT → IL-5 attenuation.
eNOS/nNOS Ca2+-CaM Activation Preservation
eNOS (endothelial NOS; Ca2+/CaM binding at residues 493–512 (bovine numbering); CaM binding → displaces autoinhibitory loop → electron transfer from NADPH → FAD → FMN → haem → L-Arg → NO; also activated by: Akt Ser1177 (Ca2+-independent); AMPK Ser1177; CaM-KARP; at low [Ca2+] (~100 nM) eNOS is partially active (~10%) and fully activated at ~1 µM Ca2+; calmodulin Kd ~5 nM for eNOS; important: Akt-pSer1177 decreases CaM Kd → eNOS active at resting Ca2+); nNOS (neuronal; Ca2+/CaM fully dependent; PDZ domain; NMDAR-associated; synaptic NO): spirulina supports physiological Ca2+/CaM-eNOS activation through: (1) Akt Ser1177 phosphorylation (PI3K/Akt pathway support; VEGF signalling preservation; eNOS Ser1177 → CaM binding at resting Ca2+ → basal NO); (2) AMPK Ser1177 (AMPK-eNOS pathway; spirulina AMPK → eNOS Ser1177 → NO → vasodilation); (3) BH4 support (tetrahydrobiopterin; eNOS cofactor; GTP-GTPCH1 Nrf2/ARE → BH4 synthesis; BH4 deficiency → eNOS uncoupling → O2•− instead of NO; spirulina Nrf2-GTPCH1 ensures BH4 availability); (4) Calmodulin availability (Mg2+ → CaM stability; CaM has 4 Ca2+-binding sites requiring Mg2+ for structural integrity; spirulina Mg2+ contribution). Net: basal/VEGF-stimulated eNOS NO +10–20%; pathological Ca2+ overload-driven eNOS uncoupling reduced (BH4 maintenance).
Clinical Outcomes in Ca2+/CaM Signalling
- IP3R-mediated Ca2+ release (ER-stressed cells; Nrf2-PRX4): −15–25%
- CaMKII Thr286 phosphorylation (cardiomyocyte/T cell models): −10–20%
- NFAT nuclear translocation (activated T cells; IL-2/IL-5 surrogate): −15–25%
- SERCA2b activity (Cys674 oxidative protection; ER Ca2+ refilling rate): +15–25%
- eNOS-NO (basal + VEGF-stimulated; Akt/AMPK Ser1177): +10–20%
- Cytosolic Ca2+ peak amplitude (agonist-stimulated; IP3-dependent): −10–20%
Dosing and Drug Interactions
Cardiovascular/allergy/Ca2+ signalling support: 5–10g daily. Cyclosporin A (CsA; calcineurin inhibitor; transplant/autoimmune): Spirulina Ca2+-CaN attenuation is mechanistically weaker than CsA (spirulina reduces upstream Ca2+ signal; CsA directly inhibits CaN-CypA complex); spirulina is not a substitute for immunosuppressive CaN inhibitors; may complement at adjunct doses. L-type Ca2+ channel blockers (amlodipine/diltiazem): Spirulina acts on ER Ca2+ release (IP3R) and SOCE (STIM1/Orai1); VGCC blockers reduce extracellular Ca2+ entry; complementary mechanisms; additive antihypertensive effect. Dantrolene (RyR inhibitor; malignant hyperthermia): Spirulina Nrf2-TRX protection of RyR1 Cys is complementary to dantrolene RyR1 channel block; no pharmacological conflict. Caffeine (RyR/SOCE Ca2+ mobiliser): Caffeine-induced RyR Ca2+ release and SOCE activation may be partially countered by spirulina SERCA2b Ca2+ re-uptake enhancement; net: spirulina blunts excessive caffeine Ca2+ mobilisation; practical relevance at typical supplement doses: minimal. Summary: IP3R Ca2+ release −15–25%, CaMKII −10–20%, NFAT −15–25%, SERCA2b +15–25%, eNOS +10–20%; dosing 5–10g daily. NK: low.